ET-12 PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

BACKGROUND: Glioblastomas are highly vascularized with elevated VEGF expression and have been shown to respond to the anti-VEGF antibody bevacizumab. High MET expression has been associated with shorter progression-free survival (PFS) in glioblastomas (Pierscianek, et al. Brain Pathol 2013). This ph...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Cloughesy, Tim, Finocchiaro, Gaetano, Belda-Iniesta, Cristobel, Recht, Lawrence, Brandes, Alba A, Pineda, Estela, Mikkelsen, Tom, Chinot, Olivier, Balana, Carmen, Macdonald, David, Westphal, Manfred, Hopkins, Kirsten, Weller, Michael, Bruey, Jean-Marie, Liu, Bo, Verret, Wendy
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2014
Teme:
Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218107/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou255.12
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki